EDAP (MCAP $28 M) FDA APPROVAL FOR PROSTATE CANCER CURE IN 2013 = NEXT SRPT
THIS UNDISCOVERED GOLDMINE IS FLYING UNDER RADAR . FDA APPROVAL FOR THEIR PROSTATE CANCER DEVICE EPCTED IN MID 2013 WILL PUSH THIS STOCK TO $10-15 EASILY . THIS IS A ONCE IN A LIFETIME OPPORTUNITY AT CURRENT BIG BARGAIN LEVEL !
Edap Tms (EDAP)
Market Cap : $28.4 Million
Cash : $10.5 Million
Price : $1.56
Shares Out : 18 M
In early November, EDAP held a productive pre-PMA meeting with the U.S. FDA to discuss the PMA submission for the Company's Ablatherm-HIFU Phase II/III clinical trial for the indication of low risk, localized prostate cancer. Based on the guidance received in this FDA interaction, EDAP is finalizing its PMA file for submission in January 2013.